Drug Shortage Report for SODIUM CHLORIDE INJECTION, USP
| Report ID | 170968 |
| Drug Identification Number | 02139510 |
| Brand name | SODIUM CHLORIDE INJECTION, USP |
| Common or Proper name | SODIUM CHLORIDE INJECTION, USP |
| Company Name | FRESENIUS KABI CANADA LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | SODIUM CHLORIDE |
| Strength(s) | 234MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 200mL |
| ATC code | B05XA |
| ATC description | I.V. SOLUTION ADDITIVES |
| Reason for shortage | Other (Please describe in comments) |
| Anticipated start date | 2022-10-03 |
| Actual start date | 2022-10-03 |
| Estimated end date | Unknown |
| Actual end date | 2022-11-30 |
| Shortage status | Resolved |
| Updated date | 2022-12-05 |
| Company comments | Due to the early availability of our 100 mL format, effective October 3, 2022 allocations for our Sodium Chloride Injection, USP 4mEq/mL Maxivial® 200 mL have been reduced. Contract customers are allocated 100% of historical monthly demand of the 200 mL only. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v5 | 2022-12-05 | French | Compare |
| v4 | 2022-12-05 | English | Compare |
| v3 | 2022-10-04 | English | Compare |
| v2 | 2022-10-03 | French | Compare |
| v1 | 2022-10-03 | English | Compare |
Showing 1 to 5 of 5